HEC Pharma Overturns Patent Decision Against Novartis’ Gilenya
China-based generics firm HEC Pharma has managed to overturn a previous final decision in a...
NYSE: NVS
Novartis Partners with Beijing’s Changping District to Expand Drug Development
Swiss pharma giant Novartis (NYSE: NVS) has partnered with Beijing’s Changping district government to expand...
Novartis Aims for China to Be Second – Largest Market by 2024
Dan Brindle, head of Novartis AG’s (NYSE: NVS) China operations, recently spoke with Xinhua news...
Novartis Q2 Results Show 5% Growth, Led by Entresto and Cosentyx
Swiss pharma giant Novartis (NYSE: NVS) reported a 5% year-on-year (YOY) revenue increase in constant...
Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment
Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...
Novartis Cuts Back on US Development of BeiGene’s PD-1 Inhibitor Tislelizumab
Novartis AG (NYSE: NVS), BeiGene’s partner, revealed in its Q3 2022 earnings report that it...
Novartis Sees 15% Global Sales Growth and Significant Investment in China for 2006
Novartis (NYSE: NVS), a multinational pharmaceutical giant, has reported a robust sales revenue of nearly...